Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model

ABSTRACT The lack of new antibiotics has prompted investigation of the combination of two existing agents—cefepime, a broad-spectrum cephalosporin, and tazobactam—to broaden their efficacy against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. We determined the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the combination in a murine neutropenic thigh model in order to establish its exposure-response relationships (ERRs). The PK of cefepime were determined for five doses; that of tazobactam was determined in earlier studies (Melchers et al., Antimicrob Agents Chemother 59:3373–3376, 2015, https://doi.org/10.1128/AAC.04402-14 ). The PK were linear for both compounds. The estimated mean (standard deviation [SD]) half-life of cefepime was 0.33 (0.12) h, and that of tazobactam was 0.176 (0.026) h; the volumes of distribution (V) were 0.73 liters/kg and 1.14 liters/kg, respectively. PD studies of cefepime administered every 2 h (q2h) with or without tazobactam, including dose fractionation studies of tazobactam, were performed against six ESBL-producing isolates. A sigmoidal maximum-effect (Emax) model was fitted to the data. In the dose fractionation study, the q2h regimen was more efficacious than the q4h and q6h regimens, indicating time-dependent activity of tazobactam. The threshold concentration (CT) best correlating with tazobactam efficacy was 0.25 mg/liter, as evidenced by the best fit of the percentage of time above the threshold concentration (%fT>CT) and response. A mean %fT>CT of 24.6% (range, 11.4 to 36.3%) for a CT of 0.25 mg/liter was required to obtain a bacteriostatic effect. We conclude that tazobactam enhanced the effect of cefepime in otherwise resistant isolates of Enterobacteriaceae and that the %fT>CT of 0.25 mg/liter best correlated with efficacy. These studies provide the basis for the development of human dosing regimens for this combination.

[1]  J. Mouton,et al.  Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model , 2016, Antimicrobial Agents and Chemotherapy.

[2]  S. Seyedmousavi,et al.  Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection , 2015, Antimicrobial Agents and Chemotherapy.

[3]  S. Seyedmousavi,et al.  Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice , 2015, Antimicrobial Agents and Chemotherapy.

[4]  D. Nicolau,et al.  In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae , 2015, Antimicrobial Agents and Chemotherapy.

[5]  M. Motyl,et al.  Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model , 2014, Antimicrobial Agents and Chemotherapy.

[6]  D. Nicolau,et al.  Unexpected In Vivo Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model , 2014, Antimicrobial Agents and Chemotherapy.

[7]  Ronald N. Jones,et al.  Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane , 2013, Antimicrobial Agents and Chemotherapy.

[8]  D. Nicolau,et al.  Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers , 2013, Antimicrobial Agents and Chemotherapy.

[9]  Ronald N. Jones,et al.  Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model , 2013, Antimicrobial Agents and Chemotherapy.

[10]  S. Sood.  Comparative Evaluation of the in-vitro Activity of Six β-lactam/β-lactamase Inhibitor Combinations against Gram Negative Bacilli. , 2013, Journal of clinical and diagnostic research : JCDR.

[11]  W. Craig,et al.  In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice , 2012, Antimicrobial Agents and Chemotherapy.

[12]  Virna J. A. Schuck,et al.  Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa , 2012, Antimicrobial Agents and Chemotherapy.

[13]  A. Vinks,et al.  Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo , 2007, Antimicrobial Agents and Chemotherapy.

[14]  J. V. D. van der Meer,et al.  Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. , 2007, The Journal of antimicrobial chemotherapy.

[15]  Andres F Zuluaga,et al.  Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases , 2006, BMC infectious diseases.

[16]  D. Nicolau,et al.  Determination of the In Vivo Pharmacodynamic Profile of Cefepime against Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli at Various Inocula , 2004, Antimicrobial Agents and Chemotherapy.

[17]  S. Miyazaki,et al.  Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models , 2004, Antimicrobial Agents and Chemotherapy.

[18]  W. Craig.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.

[19]  W. Craig,et al.  Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo , 1999, Antimicrobial Agents and Chemotherapy.

[20]  K. Fuursted,et al.  Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model. , 1997, The Journal of antimicrobial chemotherapy.

[21]  S. Leigh,et al.  Comparison of analytical performance and biological variability of three bone resorption assays. , 1997, Clinical chemistry.

[22]  F. Ramisse,et al.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections , 1996, Antimicrobial agents and chemotherapy.

[23]  M. Dudley.  Combination beta-lactam and beta-lactamase-inhibitor therapy: pharmacokinetic and pharmacodynamic considerations. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[24]  H. Mattie,et al.  Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo , 1992, Antimicrobial Agents and Chemotherapy.

[25]  R. van Furth,et al.  Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo , 1990, Antimicrobial Agents and Chemotherapy.

[26]  R. Fass,et al.  Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate , 1989, Antimicrobial Agents and Chemotherapy.